Dulta 30 Mg. 60 Mg 30 mg. 60 mg DELAYED RELEASE CAPSULES
PDF Leaflet Revision Date: 09 October 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of depression and diabetic peripheral neuropathic pain.
Dosage (summary)
60 mg once daily; initial dose 30 mg for renal/hepatic impairment.
Onset of Action / Duration
Onset: 2-4 weeks, Duration: Not specified.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; may cause neonatal withdrawal symptoms.
Key Drug Interactions
- MAOIs
- CYP1A2 inhibitors
- CYP2D6 inhibitors
- Serotonergic medicines
Contraindications
- Hypersensitivity to duloxetine
- Children under 18
- Severe hepatic impairment
- Severe renal impairment
Common side effects
- Nausea
- Headache
- Dry mouth
- Somnolence
- Dizziness
Counselling Points
- Monitor for suicidal thoughts
- Avoid abrupt discontinuation
- Caution with alcohol and CNS depressants
Serious warnings
- Risk of suicidal thoughts
- Serotonin syndrome
- Hyponatraemia
- Increased blood pressure
Important Disclaimer
The Dulta 30 Mg. 60 Mg 30 mg. 60 mg DELAYED RELEASE CAPSULES professional information leaflet below is the property of Pharma Dynamics and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
